Helper-Dependent Adenoviral Vectors: Recent Advances and Emerging Applications

Area of Science:

• Gene Therapy
• Viral Vector Technology
• Biotechnology

Background:

• Helper-dependent adenoviral vectors (HDAdVs) possess a large packaging capacity (up to 35 kb) for therapeutic DNA delivery.
• HDAdVs enable the transfer of complex, large, or multiple transgenes, facilitating advanced gene therapy applications.
• Despite production complexities, HDAdVs have undergone extensive preclinical evaluation and are now entering clinical trials.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in HDAdV technology.
• To summarize key strategies in vector development, including capsid engineering and production improvements.
• To review preclinical in vivo studies, focusing on vector design, target indications, and therapeutic outcomes.

Main Methods:

• Review of recent literature on HDAdV vector development and applications.
• Analysis of preclinical in vivo studies focusing on liver and hematopoietic stem cell targeting.
• Highlighting of ongoing clinical trials for knee osteoarthritis, chronic granulomatous disease, and solid tumors.

Main Results:

• HDAdVs demonstrate potential in preclinical models targeting the liver and hematopoietic stem cells.
• Exploration of HDAdVs for additional organ systems and vaccination strategies is ongoing.
• Three clinical trials are actively investigating HDAdVs for osteoarthritis, CGD, and cancer.

Conclusions:

• HDAdV vector systems show significant promise for treating diverse diseases.
• Continued advancements in next-generation adenoviral platforms and precision gene therapy are crucial.
• Addressing challenges in large-scale manufacturing, vector targeting, and immune responses is essential for clinical translation.